Free Trial
NASDAQ:LNSR

LENSAR Q3 2025 Earnings Results & Report

LENSAR logo
$5.00 +0.30 (+6.38%)
Closing price 11/13/2026 04:00 PM Eastern
Extended Trading
$5.02 +0.02 (+0.42%)
As of 11/13/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

LENSAR missed analyst expectations on both earnings and revenue in its Q3 2025 results, released November 6, 2025. The company reported EPS of -$0.31 versus the -$0.08 consensus estimate, while revenue of $14.32 million fell short of the $17.75 million estimate by $3.43 million.

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

LENSAR EPS Results

Actual EPS
-$0.31
Consensus EPS
-$0.08
Beat/Miss
Missed by -$0.23
One Year Ago EPS
N/A
EPS Beat Rate
2 of last 8 quarters

LENSAR Revenue Results

Actual Revenue
$14.32 million
Expected Revenue
$17.75 million
Beat/Miss
Missed by -$3.43 million
YoY Revenue Growth
N/A

LENSAR Q3 2025 Earnings FAQ

LENSAR (NASDAQ:LNSR) reported earnings of -$0.31 per share for Q3 2025, missing the consensus estimate of -$0.08. The report was announced on Thursday, November 6, 2025.

LENSAR reported revenue of $14.32 million for Q3 2025, against a consensus estimate of $17.75 million.

LENSAR Earnings Headlines

LENSAR (NASDAQ:LNSR) Rating Lowered to Sell at Wall Street Zen
Contrasting LENSAR (LNSR) and The Competition
My public warning after 55 years of watching the markets
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
BTIG Research Issues Pessimistic Forecast for LENSAR (NASDAQ:LNSR) Stock Price
See More LENSAR Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like LENSAR? Sign up for Earnings360's daily newsletter to receive timely earnings updates on LENSAR and other key companies, straight to your email.

About LENSAR

LENSAR (NASDAQ:LNSR) develops and markets laser-based technology for ophthalmic surgery, with a focus on procedures used to treat cataracts. Its systems are designed to assist surgeons with key steps in cataract surgery, including the creation of incisions and the fragmentation of the eye’s natural lens.

The company’s products include the ALLY Adaptive Cataract Treatment System and the LENSAR Laser System, which use imaging and software to support surgical planning and treatment. LENSAR also offers related software, accessories and services for ophthalmic practices and surgical facilities.

Based in Orlando, Florida, LENSAR serves eye surgeons and healthcare providers in the United States and international markets. The company was founded in 2004 and focuses on developing technology intended to support precision and workflow in cataract surgery.

View LENSAR Profile